Still long, or bag holder, but i take zero comfort from "did not meet the rigorous academic requirements in confirming the primary endpoint."

For me it is the clearly stated intention to still develop the drug, though i suppose that could change, and what seems to be a lack of major insider selling, which could also change, i guess. And the combined post hoc analyses and other data to date that seem collectively to say there is something there.

Still, if they really thought it was good money thrown after bad.... it just seems they would throw in the towel at some point. And maybe they will.

But i think not yet.

Just my two cents.

Side note. Lots going on right now. Transcript may be late. I don't expect much meat (or broccoli) in the scripted presentation anyway, but who knows. I think this time the observations of those present and the Q&A, which i don't get in the webcast, will be more relevant.